Cellular, Tissue, and Gene Therapies Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments – Biologics License Application (BLA) 125827, from Replimune, Inc. for vusolimogene oderparepvec.
🏛 Food and Drug Administration (FDA)FDA-2026-N-7231
Documents
3
Total comments
260
130 awaiting analysis
Comment status
Closed
Last activity
Jul 24, 2026
In this docket
Documents
Rules, notices, and supporting material — the primary rule pinned first.
- Notice· Jul 24, 2026No comment period
- Notice· Jul 8, 2026Closed on Jul 30, 2026💬 130